Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

GRTX - Galera Therapeutics Inc Stock Price, Fair Value and News

$0.020.00 (0.00%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

GRTX Price Action

Last 90 days

-33.3%

Trailing 12 Months

-75%

GRTX RSI Chart

2025FebMarAprMayJunJulAug020406080100

GRTX Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.11

EV/EBITDA

0.12

Price/Free Cashflow

-0.18

MarketCap/EBT

-0.05

GRTX Price/Sales (Trailing)

2020202120220102030405060

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GRTX Fundamentals

GRTX Earnings

Earnings (TTM)

-13.2M

Earnings Growth (Yr)

73.55%

Earnings Growth (Qtr)

32.47%

2019202020212022202320242025-80M-60M-40M-20M

GRTX Profitability

Return on Equity

8.91%

Return on Assets

-217.91%

Free Cashflow Yield

-552%

GRTX Investor Care

Shares Dilution (1Y)

38.74%

Diluted EPS (TTM)

-0.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs

About Galera Therapeutics Inc

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
 CEO
 WEBSITEgaleratx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES31

Galera Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Galera Therapeutics Inc? What does GRTX stand for in stocks?

GRTX is the stock ticker symbol of Galera Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Galera Therapeutics Inc (GRTX)?

As of Mon Sep 22 2025, market cap of Galera Therapeutics Inc is 1.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GRTX stock?

You can check GRTX's fair value in chart for subscribers.

Is Galera Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether GRTX is over valued or under valued. Whether Galera Therapeutics Inc is cheap or expensive depends on the assumptions which impact Galera Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRTX.